Company Idorsia Ltd

Equities

IDIA

CH0363463438

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Group companies

Sector

Sales per region

Ratings for Idorsia Ltd

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Swiss Exchange Other stock markets 16:31:30 26/04/2024 BST			5-day change	1st Jan Change
1.9 ^CHF	+9.07%		-3.55%	-10.12%

04-26	Idorsia Gets EU Medicines Regulator's Positive Opinion for Resistant Hypertension Treatment	MT
04-11	Swiss Market Index Falls as ECB Signals June Rate Cut	MT

Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.

Number of employees: 650

CHF in Million	2021	Weight	2022	Weight	Delta
Drugs 100.0 %	35	100.0 %	97	100.0 %	+174.70%

CHF in Million	2021	Weight	2022	Weight	Delta
Switzerland 48.0 %	35	100.0 %	47	48.0 %	+31.77%
Japan 45.3 %	-	-	44	45.3 %	-
United States 5.7 %	-	-	6	5.7 %	-
Rest of World 1.0 %	0	0.0 %	1	1.0 %	-

Managers	Title	Age	Since
Jean-Paul Clozel CEO	Chief Executive Officer	69	31/05/17
André Muller DFI	Director of Finance/CFO	60	31/05/17
Martine Clozel CTO	Chief Tech/Sci/R&D Officer	68	31/05/17
Andrew C. Weiss IRC	Investor Relations Contact	55	31/05/17
Alberto Gimona PRN	Corporate Officer/Principal	64	31/01/19
Julien Gander LAW	General Counsel	45	-
Alexander Khatuntsev HRO	Human Resources Officer	45	31/05/17
Simon Jose PRN	Corporate Officer/Principal	58	30/11/18

Members of the board	Title	Age	Since
Jörn Aldag BRD	Director/Board Member	65	12/05/20
Peter Kellogg BRD	Director/Board Member	67	11/05/21
Jean-Paul Clozel CEO	Chief Executive Officer	69	31/05/17
Felix R. Ehrat BRD	Director/Board Member	67	12/05/20
Sandy Mahatme BRD	Director/Board Member	59	12/05/20
Mathieu Simon CHM	Chairman	67	02/05/19
Srishti Gupta BRD	Director/Board Member	47	11/05/21
Sophie Kornowski-Bonnet BRD	Director/Board Member	61	03/05/23

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	188,844,867	110,902,769 ( 58.73 %)	9,653,500 ( 5.112 %)	58.73 %

Name	Equities	%	Valuation
Clozel Family 25.77 %	48,596,772	25.77 %	153 M CHF
JOHNSON & JOHNSON 5.081 %	9,581,882	5.081 %	30 M CHF
IDORSIA LTD 4.799 %	9,049,500	4.799 %	28 M CHF
Rudolf Maag 4.774 %	9,002,083	4.774 %	28 M CHF
Astaris Capital Management LLP 2.590 %	4,885,000	2.590 %	15 M CHF
Rossier, Mari & Associates AG 0.5144 %	970,000	0.5144 %	3 M CHF
Banque Cantonale de Genève (Investment Management) 0.4551 %	858,160	0.4551 %	3 M CHF
Finreon AG 0.2129 %	401,513	0.2129 %	1 M CHF
Mirabaud Asset Management (Suisse) SA 0.1641 %	309,411	0.1641 %	971 482 CHF
Storebrand Asset Management AS 0.1503 %	283,415	0.1503 %	889 861 CHF

Name	Equities	%	Valuation
IDORSIA LTD 4.80%	9,049,500	4.80%	28,413,439 $
SANTHERA PHARMACEUTICALS HOLDING AG 10.31%	1,301,128	10.31%	14,113,492 $

Idorsia Ltd.

Hegenheimermattweg 91

4123, Allschwil

+41 58 844 10 10

http://www.idorsia.com

Name	Category and Sector
Idorsia Pharmaceuticals Ltd. Idorsia Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Idorsia Ltd., Idorsia Pharmaceuticals Ltd. is a Swiss company that aims to discover, develop, and provide innovative medicines to patients. The private company is based in Allschwil, Switzerland. The company has created an eBook that provides useful information about Fabry disease, a rare inherited disorder caused by the build-up of a fat-like substance in the cells of the body organs. Jean-Paul Clozel has been the CEO of the company since 2017.	Pharmaceuticals: Major

Name

Category and Sector

Pharmaceuticals: Major

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Sell

Buy

Mean consensus

UNDERPERFORM

Number of Analysts

Last Close Price

1.9 CHF

Average target price

1.724 CHF

Spread / Average Target

-9.28%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
IDORSIA LTD	-10.12%	371M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs